Observational Registry Data on GIST Patients

Status Recruiting

Clinical Trial Summary

This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.

Clinical Trial Description

Research question and objectives: This study is to collect and describe real-world data for Taiwanese GIST on: - Prevalence and demographic characteristics of Taiwanese GIST - Treatment pattern of GIST therapies - Bio-marker and/or gene expression characteristics of Taiwanese GIST - Treatment outcome of TKI therapies, including recurrence-free, progression-free and overall survival - Safety profile for TKI therapies Study design: Retrospective and prospective observational cohort study Population: Taiwan GIST patients during 01 January 2010 to 31 December 2020 Data sources: Medical records and investigator-established data bank Study size: Data from up to 3,000 eligible subjects will be collected Data analysis: Descriptive statistics for longitudinally assess nationwide trends on current and evolving diagnostic, treatment, and outcome measures in the GIST population and estimate the prevalence of GIST in Taiwan. Milestones: Interim report before 31 December 2018 and final study report before 30 June 2026. ;

Study Design

Related Conditions & MeSH terms

Gastrointestinal Stromal Tumors

Clinical Trial Details

NCT number	NCT03602092
Study type	Observational [Patient Registry]
Source	National Health Research Institutes, Taiwan
Contact	Hui-Jen Tsai, M.D
Phone	886-06-2083427
Email	hjtsai@nhri.org.tw
Status	Recruiting
Phase
Start date	October 16, 2018
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05385549` - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	Phase 2
Recruiting	`NCT05905887` - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor	Phase 2
Completed	`NCT01933958` - Regorafenib Post-marketing Surveillance in Japan
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT01440959` - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258	Phase 2
Completed	`NCT00718562` - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib	Phase 2
Completed	`NCT00385203` - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).	Phase 2
Completed	`NCT00137449` - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor	Phase 2
Completed	`NCT00237172` - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)	Phase 2
Terminated	`NCT04409223` - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib	Phase 3
Active, not recruiting	`NCT03556384` - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)	Phase 2
Recruiting	`NCT04106024` - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial	Phase 2
Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
Completed	`NCT01114087` - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility	N/A
Recruiting	`NCT05366816` - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Phase 2
Recruiting	`NCT05197933` - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach	N/A
Completed	`NCT02931929` - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT	Phase 1/Phase 2
Withdrawn	`NCT05080621` - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Phase 1/Phase 2
Completed	`NCT02607332` - Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib	Phase 2
Completed	`NCT02638766` - Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	Phase 2